The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.

On this news, shares of Alnylam fell as much as $81.25 or 28.35% in intraday trading on July 30, 2026, thereby injuring investors.